ET-101 Platform
Parkinson’s, Huntington’s, MS, TBI, Alzheimer’s
DiscoveryActive
Key Facts
Indication
Parkinson’s, Huntington’s, MS, TBI, Alzheimer’s
Phase
Discovery
Status
Active
Company
About Eikonoklastes Therapeutics
Eikonoklastes Therapeutics is a private, pre-clinical biotech founded in 2019 and based in Cambridge, USA, developing first-in-class gene therapies for neurodegenerative diseases. Its lead candidate, ET-101 (SynCav1), is a gene supplement therapy designed to overexpress Caveolin-1 to promote neuroprotection and synaptic function, with a planned First-in-Human trial in ALS slated for 2025. The company's strategy focuses on pursuing accelerated approvals in rare neurological disorders like ALS, where significant unmet need and compelling preclinical data create a path for rapid development and potential value creation.
View full company profile